Acadia Pharmaceuticals diskutieren
Acadia Pharmaceuticals
WKN: 603035 / Symbol: ACAD / Name: ACADIA Pharm / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
23,21 €
-1,30 %
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "outperform" rating re-affirmed by analysts at Citigroup Inc..
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target raised by analysts at Royal Bank Of Canada from $39.00 to $40.00. They now have an "outperform" rating on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $15.00 to $17.00. They now have a "sell" rating on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was given a new $36.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target raised by analysts at UBS Group AG from $36.00 to $39.00. They now have a "buy" rating on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target raised by analysts at TD Cowen from $35.00 to $39.00. They now have a "buy" rating on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target lowered by analysts at Needham & Company LLC from $30.00 to $28.00. They now have a "buy" rating on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target lowered by analysts at JPMorgan Chase & Co. from $34.00 to $33.00. They now have an "overweight" rating on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target raised by analysts at Needham & Company LLC from $28.00 to $29.00. They now have a "buy" rating on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target lowered by analysts at Royal Bank Of Canada from $34.00 to $32.00. They now have an "outperform" rating on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target lowered by analysts at JPMorgan Chase & Co. from $33.00 to $31.00. They now have an "overweight" rating on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Ratings data for ACAD provided by MarketBeat
Neueste Beiträge
Barclays_PLC in Mettler-Toledo Intl diskutieren